Jaguar Health, Inc.(JAGX)Earnings, Financials & Key Ratios
JAGX•NASDAQ
$2.82
$187925 mkt cap·Price updated May 6, 2026
AboutJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.Show more
- Revenue$12M-1.5%
- EBITDA-$54M-89.4%
- Net Income-$54M-39.2%
- EPS (Diluted)-803.95+82.4%
- Gross Margin67.21%-19.3%
- EBITDA Margin-468.43%-92.3%
- Operating Margin-398.82%-51.2%
- Net Margin-465.42%-41.3%
- ROIC-116.78%-78.1%
- Interest Coverage-565.60-234.8%
JAGX Key Insights
Jaguar Health, Inc. (JAGX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 50.2% free cash flow margin
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
JAGX Price & Volume
Jaguar Health, Inc. (JAGX) stock price & volume — 10-year historical chart
Loading chart...
JAGX Growth Metrics
Jaguar Health, Inc. (JAGX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years46.18%
5 Years4.17%
3 Years-1.26%
TTM-1.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-39.18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM99.32%
Return on Capital
10 Years-176.02%
5 Years-150.67%
3 Years-169.08%
Last Year-292.5%
JAGX Peer Comparison
Jaguar Health, Inc. (JAGX) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 | |
 PAHC | 2.38B | 58.64 | 49.28 | 27.37% | 6.29% | 30.81% | 2.67 | |
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 IRWD | 787.57M | 4.83 | 32.20 | -15.72% | 8.11% | |||
 PTGX | 6.63B | 103.97 | -50.72 | -89.41% | -6.48% | -17.76% | 0.02 | |
 ARRY | 1.24B | 8.12 | -11.13 | 40.22% | -5.56% | -20.64% | 2.94 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 VNDA | 439.76M | 7.44 | -1.99 | 8.72% | -102.02% | -49.24% | 0.04 |
Compare JAGX vs Peers
Jaguar Health, Inc. (JAGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
JAGX Income Statement
Jaguar Health, Inc. (JAGX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 4.36M | 4.42M | 5.78M | 9.38M | 4.33M | 11.96M | 9.76M | 11.69M | 11.51M |
| Revenue Growth % | 2981.61% | 1.26% | 30.77% | 62.51% | -53.81% | 175.8% | -18.36% | 19.75% | -1.52% |
| Cost of Goods Sold | 880.4K | 2.77M | 3.82M | 3.28M | 2.33M | 2.02M | 2.04M | 1.96M | 3.77M |
| COGS % of Revenue | 20.19% | 62.63% | 66.08% | 34.95% | 53.82% | 16.89% | 20.87% | 16.73% | 32.79% |
| Gross Profit | 3.48M▲ 0% | 1.65M▼ 52.6% | 1.96M▲ 18.7% | 6.11M▲ 211.6% | 2M▼ 67.2% | 9.94M▲ 396.4% | 7.72M▼ 22.3% | 9.73M▲ 26.0% | 7.74M▼ 20.5% |
| Gross Margin % | 79.81% | 37.37% | 33.92% | 65.05% | 46.18% | 83.11% | 79.13% | 83.27% | 67.21% |
| Gross Profit Growth % | 3786.67% | -52.59% | 18.7% | 211.64% | -67.21% | 396.35% | -22.27% | 26.02% | -20.52% |
| Operating Expenses | 18.6M | 27.26M | 30.91M | 32.75M | 42.71M | 44.35M | 42.02M | 40.56M | 53.65M |
| OpEx % of Revenue | 426.51% | 617.36% | 535.19% | 348.98% | 985.24% | 370.96% | 430.44% | 347.04% | 466.03% |
| Selling, General & Admin | 14.33M | 22.11M | 20.44M | 21M | 26M | 26.7M | 23.05M | 24.02M | 27.88M |
| SG&A % of Revenue | 328.61% | 500.64% | 353.9% | 223.72% | 599.7% | 223.36% | 236.12% | 205.52% | 242.19% |
| Research & Development | 4.27M | 5.15M | 5.82M | 6.41M | 15.08M | 17.65M | 18.6M | 16.54M | 24.97M |
| R&D % of Revenue | 97.9% | 116.73% | 100.78% | 68.33% | 347.84% | 147.6% | 190.51% | 141.52% | 216.89% |
| Other Operating Expenses | 88.55K | 0 | 4.65M | 5.34M | 1.63M | 0 | 371K | 0 | 800K |
| Operating Income | -34.25M▲ 0% | -30.82M▲ 10.0% | -28.95M▲ 6.1% | -26.65M▲ 7.9% | -40.71M▼ 52.8% | -34.41M▲ 15.5% | -34.29M▲ 0.4% | -30.83M▲ 10.1% | -45.91M▼ 48.9% |
| Operating Margin % | -785.27% | -697.98% | -501.26% | -283.93% | -939.05% | -287.85% | -351.31% | -263.76% | -398.82% |
| Operating Income Growth % | -152.08% | 10% | 6.09% | 7.95% | -52.77% | 15.46% | 0.36% | 10.09% | -48.9% |
| EBITDA | -33.66M | -29.08M | -27.02M | -24.37M | -38.9M | -32.12M | -33.13M | -28.47M | -53.92M |
| EBITDA Margin % | -771.87% | -658.41% | -467.88% | -259.64% | -897.23% | -268.68% | -339.42% | -243.59% | -468.43% |
| EBITDA Growth % | -148.64% | 13.62% | 7.07% | 9.82% | -59.62% | 17.41% | -3.14% | 14.06% | -89.38% |
| D&A (Non-Cash Add-back) | 584.34K | 1.75M | 1.93M | 2.28M | 1.81M | 2.29M | 1.16M | 2.36M | -8.01M |
| EBIT | -15.12M | -29.52M | -32.8M | -31.02M | -44.18M | -35.67M | -33.92M | -39.02M | -37.9M |
| Net Interest Income | -1.21M | -2.63M | -5.73M | -8.13M | -10.05M | -12.72M | -6.38M | -231K | 67K |
| Interest Income | 0 | 0 | 0 | 2.79M | 8.42M | 0 | 0 | 0 | 0 |
| Interest Expense | 1.21M | 2.63M | 5.73M | 2.79M | 8.42M | 12.72M | 6.38M | 231K | -67K |
| Other Income/Expense | -902.8K | -1.32M | -9.58M | -7.16M | -11.89M | -13.98M | -7.61M | -8.42M | -8.09M |
| Pretax Income | -35.15M▲ 0% | -32.15M▲ 8.5% | -38.53M▼ 19.9% | -33.81M▲ 12.3% | -52.6M▼ 55.6% | -48.4M▲ 8.0% | -41.9M▲ 13.4% | -39.25M▲ 6.3% | -54M▼ 37.6% |
| Pretax Margin % | -805.97% | -727.92% | -667.17% | -360.25% | -1213.38% | -404.78% | -429.27% | -335.79% | -469.09% |
| Income Tax | -13.18M | 0 | 10K | 0 | 0 | 0 | 0 | 0 | -422K |
| Effective Tax Rate % | 37.5% | 0% | -0.03% | 0% | 0% | 0% | 0% | 0% | 0.78% |
| Net Income | -21.97M▲ 0% | -32.15M▼ 46.3% | -38.54M▼ 19.9% | -33.81M▲ 12.3% | -52.59M▼ 55.6% | -47.45M▲ 9.8% | -41.3M▲ 13.0% | -38.49M▲ 6.8% | -53.58M▼ 39.2% |
| Net Margin % | -503.73% | -727.92% | -667.34% | -360.25% | -1213.26% | -396.91% | -423.11% | -329.3% | -465.42% |
| Net Income Growth % | -49.1% | -46.33% | -19.89% | 12.27% | -55.57% | 9.77% | 12.97% | 6.8% | -39.18% |
| Net Income (Continuing) | -21.97M | -32.15M | -38.54M | -33.81M | -52.6M | -48.4M | -41.9M | -39.25M | -53.58M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 242K | -699K | -64K | -791K | -1.4M |
| EPS (Diluted) | -999999.00▲ 0% | -999999.00▲ 0.0% | -999999.00▲ 0.0% | -999999.00▲ 0.0% | -999999.00▲ 0.0% | -999999.00▲ 0.0% | -93975.00▲ 90.6% | -4574.15▲ 95.1% | -803.95▲ 82.4% |
| EPS Growth % | 89.09% | 96.21% | 99.84% | 87.73% | 84.27% | 64.2% | 99.93% | 95.13% | 82.42% |
| EPS (Basic) | -999999.00 | -999999.00 | -999999.00 | -999999.00 | -999999.00 | -999999.00 | -93975.00 | -4574.15 | -803.95 |
| Diluted Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 441 | 8.41K | 66.64K |
| Basic Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 441 | 8.41K | 66.64K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
JAGX Balance Sheet
Jaguar Health, Inc. (JAGX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.8M | 8.15M | 9.52M | 17.79M | 28.43M | 22.32M | 27.96M | 32.2M | 20.34M |
| Cash & Short-Term Investments | 520.7K | 2.57M | 3.5M | 8.09M | 17.05M | 5.47M | 6.47M | 8M | 968K |
| Cash Only | 520.7K | 2.57M | 3.5M | 8.09M | 17.05M | 5.47M | 6.47M | 8M | 968K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 469.04K | 1M | 1.69M | 4.56M | 2.14M | 2.47M | 2.18M | 1.65M | 1.7M |
| Days Sales Outstanding | 39.26 | 82.8 | 107.07 | 177.35 | 180.52 | 75.31 | 81.67 | 51.43 | 53.84 |
| Inventory | 2.07M | 3.34M | 2.13M | 2.78M | 4.9M | 7.02M | 9.19M | 10.35M | 8.6M |
| Days Inventory Outstanding | 859.35 | 441.07 | 203.64 | 309.58 | 766.61 | 1.27K | 1.65K | 1.93K | 831.65 |
| Other Current Assets | 239.17K | 6.12K | 941K | 0 | 0 | 7.36M | 10.12M | 12.2M | 9.08M |
| Total Non-Current Assets | 39.83M | 32.89M | 26.89M | 25.05M | 24.83M | 25.13M | 22.8M | 21.23M | 17.98M |
| Property, Plant & Equipment | 1.22M | 760.62K | 710K | 677K | 1.73M | 1.7M | 1.67M | 1.4M | 1.46M |
| Fixed Asset Turnover | 3.57x | 5.81x | 8.13x | 13.86x | 2.50x | 7.05x | 5.84x | 8.35x | 7.87x |
| Goodwill | 5.21M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 33.4M | 31.71M | 26.02M | 24.34M | 22.65M | 22.44M | 20.12M | 18.48M | 16.02M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 420.83K | 154K | 37K | 446K | 995K | 1.01M | 1.35M | 494K |
| Total Assets | 43.63M▲ 0% | 41.04M▼ 5.9% | 36.41M▼ 11.3% | 42.84M▲ 17.7% | 53.27M▲ 24.3% | 47.45M▼ 10.9% | 50.76M▲ 7.0% | 53.42M▲ 5.2% | 38.32M▼ 28.3% |
| Asset Turnover | 0.10x | 0.11x | 0.16x | 0.22x | 0.08x | 0.25x | 0.19x | 0.22x | 0.30x |
| Asset Growth % | 1124.46% | -5.93% | -11.29% | 17.67% | 24.33% | -10.91% | 6.98% | 5.24% | -28.27% |
| Total Current Liabilities | 15.39M | 26.66M | 15.39M | 13.22M | 15.47M | 30.34M | 13.99M | 19.7M | 40.65M |
| Accounts Payable | 7.35M | 5.41M | 5.35M | 4.76M | 4.93M | 5.81M | 4.97M | 5.29M | 8.69M |
| Days Payables Outstanding | 3.05K | 714.53 | 511.92 | 529.58 | 771.15 | 1.05K | 891.27 | 986.9 | 840.06 |
| Short-Term Debt | 5.42M | 16.08M | 6.78M | 3.79M | 3.18M | 15.88M | 4.87M | 12.04M | 27.44M |
| Deferred Revenue (Current) | 177.39K | 4.94M | 0 | 0 | 0 | 0 | 0 | 170K | 170K |
| Other Current Liabilities | 2.17M | 373.83K | 3K | 179K | 1K | 0 | 0 | 0 | 0 |
| Current Ratio | 0.25x | 0.31x | 0.62x | 1.35x | 1.84x | 0.74x | 2.00x | 1.63x | 0.50x |
| Quick Ratio | 0.11x | 0.18x | 0.48x | 1.14x | 1.52x | 0.50x | 1.34x | 1.11x | 0.29x |
| Cash Conversion Cycle | -2.15K | -190.66 | -201.21 | -42.65 | 175.98 | 295.15 | 836.93 | 995.95 | 45.43 |
| Total Non-Current Liabilities | 10.98M | 9M | 10.35M | 12.42M | 25.94M | 18.47M | 31.88M | 27.23M | 16.36M |
| Long-Term Debt | 10.98M | 0 | 450K | 12.42M | 25.02M | 17.74M | 30.99M | 23.5M | 15.08M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 919K | 725K | 886K | 686K | 892K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 9.89M | 0 | 0 | 0 | 0 | 2.48M | 0 |
| Total Liabilities | 26.37M | 35.66M | 25.74M | 25.64M | 41.41M | 48.81M | 45.87M | 46.93M | 57.01M |
| Total Debt | 16.41M | 16.08M | 7.57M | 16.21M | 29.36M | 34.84M | 37.09M | 36.53M | 43.61M |
| Net Debt | 15.88M | 13.52M | 4.07M | 8.12M | 12.31M | 29.37M | 30.63M | 28.52M | 42.64M |
| Debt / Equity | 0.95x | 2.99x | 0.71x | 0.94x | 2.48x | - | 7.57x | 5.62x | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -12.50x | -11.23x | -5.72x | -11.11x | -5.25x | -2.80x | -5.31x | -168.92x | -565.60x |
| Total Equity | 17.26M▲ 0% | 5.38M▼ 68.8% | 10.67M▲ 98.3% | 17.2M▲ 61.2% | 11.85M▼ 31.1% | -1.36M▼ 111.4% | 4.9M▲ 461.1% | 6.49M▲ 32.6% | -18.69M▼ 387.8% |
| Equity Growth % | 803.33% | -68.81% | 98.27% | 61.17% | -31.1% | -111.44% | 461.14% | 32.61% | -387.77% |
| Book Value per Share | - | - | - | - | - | - | 11104.31 | 771.72 | -280.43 |
| Total Shareholders' Equity | 17.26M | 5.38M | 10.67M | 17.2M | 11.61M | -657K | 4.96M | 7.29M | -17.29M |
| Common Stock | 10.53K | 6.49K | 5K | 4K | 0 | 0 | 0 | 0 | 1K |
| Retained Earnings | -62.4M | -94.55M | -133.09M | -166.9M | -219.49M | -266.95M | -308.25M | -346.48M | -399.92M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -43.63T | -9T | 0 | 0 | 0 | -680K | -652K | -467K | -833K |
| Minority Interest | 0 | 0 | 0 | 0 | 242K | -699K | -64K | -791K | -1.4M |
JAGX Cash Flow Statement
Jaguar Health, Inc. (JAGX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.82M | -22.73M | -20.46M | -15.28M | -34.97M | -33.1M | -33.24M | -29.38M | 5.8M |
| Operating CF Margin % | -225.28% | -514.72% | -354.23% | -162.79% | -806.69% | -276.88% | -340.56% | -251.38% | 50.37% |
| Operating CF Growth % | 31.84% | -131.36% | 10% | 25.32% | -128.89% | 5.34% | -0.42% | 11.61% | 119.73% |
| Net Income | -21.97M | -32.15M | -38.54M | -33.81M | -52.6M | -49.08M | -41.87M | -39.03M | -15.37M |
| Depreciation & Amortization | 584.34K | 1.32M | 1.93M | 2.28M | 1.81M | 2.29M | 2.39M | 2.36M | 3K |
| Stock-Based Compensation | 814.61K | 2.02M | 2.99M | 2.82M | 3.97M | 3.32M | 2.11M | 1.64M | -810K |
| Deferred Taxes | -13.18M | 5.75M | 0 | 0 | 4.39M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 19.8M | 1.25M | 13.83M | 16.89M | 5.19M | 14.79M | 15.23M | 8.66M | 9.09M |
| Working Capital Changes | 4.13M | -925.1K | -662K | -3.47M | 2.27M | -4.43M | -11.1M | -3.01M | 12.89M |
| Change in Receivables | -166.06K | -528.02K | -704K | -2.87M | 2.82M | -170K | 298K | 526K | -434K |
| Change in Inventory | 128K | -1.27M | 1.21M | -653K | -2.12M | -2.12M | -2.17M | -1.16M | 902K |
| Change in Payables | 4.19M | -1.94M | -63K | -743K | 158K | 902K | -855K | 328K | 3.02M |
| Cash from Investing | -1.29M | -6.53K | 0 | -7K | -6K | -1.68M | 0 | -231K | 149K |
| Capital Expenditures | 0 | -6.53K | 0 | -7K | -6K | -77K | 0 | -16K | -25K |
| CapEx % of Revenue | - | 0.15% | - | 0.07% | 0.14% | 0.64% | - | 0.14% | 0.22% |
| Acquisitions | -1.56M | 0 | 0 | 0 | 247K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 272.13K | -6.53B | 0 | 0 | -247K | -1.6M | 0 | -215K | 174K |
| Cash from Financing | 10.68M | 24.55M | 21.77M | 19.49M | 43.94M | 23.18M | 34.23M | 31.2M | -44.33M |
| Debt Issued (Net) | 377.91K | 783.49K | -100K | 5.69M | 9.05M | 3.88M | -100K | -100K | -20.91M |
| Equity Issued (Net) | 10.3M | 25.88M | 12.64M | 1.95M | 33.58M | 20.46M | 32.71M | 31.91M | -23.38M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -30 | 0 | 0 | 0 | 0 | 0 | 0 | -31.07M |
| Other Financing | 0 | -2.12M | 9.23M | 11.86M | 1.31M | -1.16M | 1.62M | -608K | -44K |
| Net Change in Cash | -430.28K▲ 0% | 1.81M▲ 520.3% | 1.31M▼ 27.3% | 4.21M▲ 219.9% | 8.96M▲ 113.0% | -11.58M▼ 229.2% | 1M▲ 108.6% | 1.53M▲ 53.3% | -38.35M▼ 2601.8% |
| Free Cash Flow | -9.82M▲ 0% | -22.74M▼ 131.4% | -20.46M▲ 10.0% | -15.29M▲ 25.3% | -34.98M▼ 128.8% | -34.78M▲ 0.6% | -33.24M▲ 4.4% | -29.61M▲ 10.9% | 5.77M▲ 119.5% |
| FCF Margin % | -225.28% | -514.87% | -354.23% | -162.87% | -806.83% | -290.89% | -340.56% | -253.36% | 50.15% |
| FCF Growth % | 32.33% | -131.42% | 10.03% | 25.28% | -128.83% | 0.56% | 4.42% | 10.91% | 119.49% |
| FCF per Share | - | - | - | - | - | - | -75378.68 | -3519.31 | 86.63 |
| FCF Conversion (FCF/Net Income) | 0.45x | 0.71x | 0.53x | 0.45x | 0.66x | 0.70x | 0.80x | 0.76x | -0.11x |
| Interest Paid | 0 | 0 | 142K | 757K | 0 | 0 | 35K | 14K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
JAGX Key Ratios
Jaguar Health, Inc. (JAGX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -1515.11% | -296.74% | -283.92% | -480.05% | -242.58% | -362.04% | -904.14% | -2332.67% | -675.83% | - |
| Return on Invested Capital (ROIC) | -649.73% | -152.76% | -88.84% | -129.07% | -99.76% | -123.38% | -98.94% | -80.96% | -65.56% | -116.78% |
| Gross Margin | 63.28% | 79.81% | 37.37% | 33.92% | 65.05% | 46.18% | 83.11% | 79.13% | 83.27% | 67.21% |
| Net Margin | -10410.87% | -503.73% | -727.92% | -667.34% | -360.25% | -1213.26% | -396.91% | -423.11% | -329.3% | -465.42% |
| Debt / Equity | - | 0.95x | 2.99x | 0.71x | 0.94x | 2.48x | - | 7.57x | 5.62x | - |
| Interest Coverage | -13.79x | -12.50x | -11.23x | -5.72x | -11.11x | -5.25x | -2.80x | -5.31x | -168.92x | -565.60x |
| FCF Conversion | 0.98x | 0.45x | 0.71x | 0.53x | 0.45x | 0.66x | 0.70x | 0.80x | 0.76x | -0.11x |
| Revenue Growth | -45.23% | 2981.61% | 1.26% | 30.77% | 62.51% | -53.81% | 175.8% | -18.36% | 19.75% | -1.52% |
JAGX Frequently Asked Questions
Jaguar Health, Inc. (JAGX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Jaguar Health, Inc. (JAGX) reported $11.5M in revenue for fiscal year 2025.
Jaguar Health, Inc. (JAGX) saw revenue decline by 1.5% over the past year.
Jaguar Health, Inc. (JAGX) reported a net loss of $53.6M for fiscal year 2025.
Dividend & Returns
Jaguar Health, Inc. (JAGX) had negative free cash flow of $23.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More JAGX
Jaguar Health, Inc. (JAGX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates